Q-omics provides the consensus-scored RAB7B profile across patient tissues and cancer cell-line models. RAB7B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RAB7B is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RAB7B RNA expression shows 17,426 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where RAB7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB7B survival associations across molecular data types. RAB7B RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB7B RNA expression–survival associations across cancer types. High RAB7B expression shows unfavorable associations in UVM, UCEC, ACC and OV, but favorable associations in LAML and MESO. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RAB7B RNA expression.
This table summarizes RAB7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RAB7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB7B shows lower tumor expression in BRCA and UCEC and higher tumor expression in KIRC, KIRP, LIHC and HNSC. The KIRC box plot shows higher RAB7B RNA expression in tumor versus normal tissue (log2 FC = +1.837, t-test p < 0.001).
This table shows molecular features associated with RAB7B in patient tissues and cancer cell lines. In patient samples, RAB7B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
